Rafferty Asset Management
VYGR icon

Rafferty Asset Management’s Voyager Therapeutics VYGR Stock Holding History

Rafferty Asset Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-89,242
Closed -$706K – 1195
2024
Q2 		$706K Sell
89,242
-29,974
-25% -$251K ﹤0.01% 880
2024
Q1 		$1.11M Buy
+119,216
New +$1.01M ﹤0.01% 815
2020
Q3 		– Sell
-14,005
Closed -$177K – 1040
2020
Q2 		$177K Buy
+14,005
New +$163K ﹤0.01% 934
2020
Q1 		– Sell
-43,879
Closed -$612K – 805
2019
Q4 		$612K Sell
43,879
-48,645
-53% -$707K 0.01% 661
2019
Q3 		$1.59M Buy
92,524
+29,422
+47% +$618K 0.02% 441
2019
Q2 		$1.72M Buy
+63,102
New +$1.44M 0.03% 456

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Rafferty Asset Management's VYGR Position: Q3 2024 in Review

Rafferty Asset Management sold out of Voyager Therapeutics (VYGR) in Q3 2024, closing a stake of 89,242 shares — an estimated $706K sold.

Rafferty Asset Management first reported a position in VYGR in Q2 2019 and held it in 6 quarters. The position peaked at $1.72M in Q2 2019. 128 funds tracked by Wall St. Rank hold VYGR as of Q3 2024.

  • Rafferty Asset Management reported no remaining Voyager Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Rafferty Asset Management sold 89,242 Voyager Therapeutics shares in Q3 2024, an estimated $706K.
  • Rafferty Asset Management first reported a position in Voyager Therapeutics in Q2 2019 and held it in 6 quarters.
  • Rafferty Asset Management's Voyager Therapeutics position peaked at $1.72M in Q2 2019.
  • 128 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2024.

Based on Rafferty Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.